Print Send My Information

Purpose

This study will evaluate the safety, efficacy, pharmacokinetics, and immunogenicity of mosunetuzumab (Mosun) + lenalidomide (Len) (Mosun + Len) in participants with follicular lymphoma (FL). This study will also compare the pharmacokinetics, pharmacodynamics, safety, efficacy, and immunogenicity of IV mosunetuzumab + len vs subcutaneous (SC) mosunetuzumab + len.

Condition

Eligibility

Eligible Ages
Over 18 Years
Eligible Genders
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • Eastern Cooperative Oncology Group (ECOG) Performance Status of 0, 1, or 2 - R/R FL after treatment with at least one prior systemic lymphoma therapy, which includes prior immunotherapy or chemoimmunotherapy - Previously untreated participants with FL must require systemic therapy assessed by investigator based on the Groupe d'Etude des Lymphomes Folliculaires (GELF) criteria and have a Follicular Lymphoma International Prognostic Index (FLIPI) score of 2-5 - Histologically documented FL of Grade 1, 2, or 3a, and that expresses CD20 at time of diagnosis as determined by the local laboratory - Fluorodeoxyglucose avid lymphoma (i.e., positron emission tomography (PET) positive lymphoma) - At least one bi dimensionally measurable nodal lesion (>1.5 cm in its largest dimension by PET- computed tomography (CT) scan), or at least one bi dimensionally measurable extranodal lesion (>1.0 cm in its largest dimension by PET-CT scan) - Availability of a representative tumor specimen and the corresponding pathology report for confirmation of the diagnosis of FL - Adequate hematologic function (unless due to underlying lymphoma, per the investigator) as defined by the protocol - Negative HIV test at screening, with the following exception: Individuals with a positive HIV test at screening are eligible provided they are stable on antiretroviral therapy for at least 4 weeks, have a CD4 count ≥ 200/mL, have an undetectable viral load, and have not had a history of opportunistic infection attributable to AIDS within the last 12 months - Normal laboratory values (unless due to underlying lymphoma) as defined by the protocol - Agreement to comply with all local requirements of the Len risk minimization plan - For women of childbearing potential: agreement to remain abstinent or use two adequate methods of contraception, including at least one method with a failure rate of < 1% per year, for at least 28 days prior to Day 1 of Cycle 1, during the treatment period, and for at least 12 months after the final dose of glofitamab, 28 days after the last dose of Len, 18 months after the last dose of G, 3 months after the final dose of tocilizumab, and 3 months after the final dose of Mosun. Women must refrain from donating eggs during this same period - For men: agreement to remain abstinent or use contraceptive measures and agreement to refrain from donating sperm, with female partners of childbearing potential or pregnant female partners, men must remain abstinent or use a condom during the treatment period and for at least 2 months after the final dose of glofitamab, 28 days after last dose of Len, 18 months after the last dose of G, 3 months after the final dose of tocilizumab, and 3 months after the final dose of Mosun

Exclusion Criteria

  • Any history of Grade 3b FL - Suspicion or clinical evidence of transformed lymphoma at enrollment by investigator assessment - Any history of disease transformation and/or diffuse large B-cell lymphoma (DLBCL) - Documented refractoriness to an obinutuzumab monotherapy containing regimen in glofitamab-containing treatment combination - Active or history of central nervous system (CNS) lymphoma or leptomeningeal infiltration - Documented refractoriness to lenalidomide, defined as no response (partial response (PR) or complete response (CR)) within 6 months of therapy - Prior standard or investigational anti-cancer therapy as specified by the protocol - Clinically significant toxicity (other than alopecia) from prior treatment that has not resolved to Grade <=2 prior to Day 1 of Cycle 1 - Known history of idiopathic pulmonary fibrosis, organizing pneumonia (e.g. bronchiolitis obliterans), drug-induced pneumonitis or evidence of active pneumonitis on screening chest CT scan - Treatment with systemic immunosuppressive medications, including, but not limited to, prednisone, azathioprine, methotrexate, thalidomide, and anti-tumor necrosis factor agents within 2 weeks prior to Day 1 of Cycle 1 - History of solid organ transplantation - History of severe allergic or anaphylactic reaction to humanized, chimeric or murine MAbs - Known sensitivity or allergy to murine products - Known hypersensitivity to biopharmaceuticals produced in Chinese hamster ovary cells or any component of the glofitamab, Mosun, G, Len, or thalidomide formulation, including mannitol - History of erythema multiforme, Grade >=3 rash, or blistering following prior treatment with immunomodulatory derivatives - Known history of idiopathic pulmonary fibrosis, organizing pneumonia, drug-induced pneumonitis or evidence of active pneumonitis on screening chest CT scan - Known active bacterial, viral, fungal, or other infection, or any major episode of infection requiring treatment with IV antibiotics within 4 weeks of Day 1 of Cycle 1 - Known or suspected chronic active Epstein-Barr virus infection or hemophagocytic syndrome - Known history of macrophage activating syndrome (MAS) or hemophagocytic lymphohistiocytosis (HLH) - Active Hepatitis B and Hepatitis C infection or autoimmune disease requiring treatment - Prior allogenic hematopoietic stem cell transplant - Known history of HIV positive status - History of progressive multifocal leukoencephalopathy - Administration of a live, attenuated vaccine within 4 weeks before first dose of study treatment or anticipation that such a live attenuated vaccine will be required during the study - Other malignancy that could affect compliance with the protocol or interpretation of results - Prior allogenic hematopoietic stem cell transplant (HSCT) - Contraindication to treatment for thromboembolism prophylaxis - Grade >=2 neuropathy - Evidence of any significant, uncontrolled concomitant disease that could affect compliance with the protocol or interpretation of results, including, but not limited to significant cardiovascular disease or significant pulmonary disease - Major surgical procedure other than for diagnosis within 28 days prior to Day 1 of Cycle 1 Day 1 or anticipation of a major surgical procedure during the course of the study - Clinically significant history of liver disease, including viral or other hepatitis, current alcohol abuse, or cirrhosis - Inadequate hematologic function - Any of the following abnormal laboratory values - Pregnant or lactating or intending to become pregnant during the study - Life expectancy < 3 months - Unable to comply with the study protocol, in the investigator's judgment - History of illicit drug or alcohol abuse within 12 months prior to screening, in the investigator's judgment - Any serious medical condition or abnormality in clinical laboratory tests that, in the investigator's or Medical Monitor's judgment, precludes the patient's safe participation in and completion of the study, or which could affect compliance with the protocol or interpretation of results

Study Design

Phase
Phase 1/Phase 2
Study Type
Interventional
Allocation
Randomized
Intervention Model
Sequential Assignment
Primary Purpose
Treatment
Masking
None (Open Label)

Arm Groups

ArmDescriptionAssigned Intervention
Experimental
Intravenous (IV) Mosunetuzumab + Lenalidomide (Non-randomized) 		Participants will receive treatment with IV mosunetuzumab plus lenalidomide for 12 cycles total (cycle length = 21 days for Cycle 1, 28 days from Cycle 2 onward)
  • Drug: Mosunetuzumab (IV)
    Participants will receive IV mosunetuzumab as defined by the study protocol
    Other names:
    • RO7030816
  • Drug: Tocilizumab
    Participants will receive IV tocilizumab as needed for adverse reactions as defined by the study protocol
    Other names:
    • RO4877533
  • Drug: Lenalidomide
    Participants will receive oral lenalidomide as defined by the study protocol
Experimental
Subcutaneous (SC) Mosunetuzumab + Lenalidomide (Non-randomized) 		Participants will receive treatment with SC mosunetuzumab plus lenalidomide for 12 cycles total (cycle length = 21 days for Cycle 1, 28 days from Cycle 2 onward). Participants that have received complete metabolic response (CMR) or partial metabolic response (PMR) after 12 cycles of induction therapy with mosunetuzumab + lenalidomide will receive maintenance therapy with SC mosunetuzumab every 8 weeks (Q8W) for an additional 9 cycles.
  • Drug: Tocilizumab
    Participants will receive IV tocilizumab as needed for adverse reactions as defined by the study protocol
    Other names:
    • RO4877533
  • Drug: Lenalidomide
    Participants will receive oral lenalidomide as defined by the study protocol
Experimental
Arm A: IV Mosunetuzumab + Len (Randomized) 		Participants will receive treatment with IV mosunetuzumab plus lenalidomide for 12 cycles total (cycle length = 21 days for Cycle 1, 28 days from Cycle 2 onward)
  • Drug: Mosunetuzumab (IV)
    Participants will receive IV mosunetuzumab as defined by the study protocol
    Other names:
    • RO7030816
  • Drug: Lenalidomide
    Participants will receive oral lenalidomide as defined by the study protocol
Experimental
Arm B: SC Mosunetuzumab + Len (Randomized) 		Participants will receive treatment with SC mosunetuzumab plus lenalidomide for 12 cycles total (cycle length = 21 days for Cycle 1, 28 days from Cycle 2 onward)
  • Drug: Lenalidomide
    Participants will receive oral lenalidomide as defined by the study protocol
  • Drug: Mosunetuzumab (SC)
    Participants will receive SC mosunetuzumab as defined by the study protocol
    Other names:
    • RO7030816

Recruiting Locations

More Details

NCT ID
NCT04246086
Status
Recruiting
Sponsor
Hoffmann-La Roche

Study Contact

Reference Study ID Number: CO41942 https://forpatients.roche.com/
888-662-6728
global-roche-genentech-trials@gene.com

Notice

Study information shown on this site is derived from ClinicalTrials.gov (a public registry operated by the National Institutes of Health). The listing of studies provided is not certain to be all studies for which you might be eligible. Furthermore, study eligibility requirements can be difficult to understand and may change over time, so it is wise to speak with your medical care provider and individual research study teams when making decisions related to participation.

For help using this page: trialstoday@researchmatch.org or call 855-514-7001

ResearchMatch is funded in part by the National Institutes of Health (NIH) Clinical and Translational Science Award (CTSA) program, led by the NIH’s National Center for Advancing Translational Sciences (NCATS), grants UL1TR000445 and 1U54RR032646-01, and grant U24TR001579 from NCATS and the National Library of Medicine. The content of this website is solely the responsibility of ResearchMatch and Vanderbilt University and does not necessarily represent the official views of the NIH, NCATS, or NLM.

Vanderbilt University Medical Center